Lawrence Otto Klein insider trades

Open-market stock purchases and sales by Lawrence Otto Klein, Chief Executive Officer at Oruka Therapeutics, Inc, from SEC Form 4 filings since Jan 2, 2019.

Recent trades

DateStockTradeValue
Oct 1, 2026ORKA Oruka Therapeutics, IncSold$1.4M
Oct 1, 2026ORKA Oruka Therapeutics, IncSold$719K
Oct 1, 2026ORKA Oruka Therapeutics, IncSold$17K
Oct 1, 2026ORKA Oruka Therapeutics, IncBought (not open market)—
Sep 15, 2026ORKA Oruka Therapeutics, IncSold$235K
Sep 1, 2026ORKA Oruka Therapeutics, IncSold$600K
Sep 1, 2026ORKA Oruka Therapeutics, IncSold$5.8M
Sep 1, 2026ORKA Oruka Therapeutics, IncSold$444K
Sep 1, 2026ORKA Oruka Therapeutics, IncBought (not open market)—
Jun 15, 2026ORKA Oruka Therapeutics, IncSold$120K
Jun 9, 2026JBIO Jade Biosciences, IncBought (not open market)—
Mar 16, 2026ORKA Oruka Therapeutics, IncSold$71.4K
Jan 23, 2026ORKA Oruka Therapeutics, IncBought (not open market)—
Jan 23, 2026ORKA Oruka Therapeutics, IncBought (not open market)—

Companies traded

  • ORKA Oruka Therapeutics, Inc: 9 sales, last Oct 1, 2026
  • JBIO Jade Biosciences, Inc: other filings, last Jun 9, 2026
  • JSPR Jasper Therapeutics, Inc: other filings, last Jun 7, 2023
  • CRSP CRISPR Therapeutics AG: 27 sales, last Aug 16, 2022
  • DYN Dyne Therapeutics, Inc: 1 buy, last Jul 5, 2022

Get free alerts when Lawrence Otto Klein files a new trade →